The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease.
Animals
Benzylamines
/ pharmacology
Cell Death
/ drug effects
Cell Line
Cell Line, Transformed
Cell Polarity
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Corpus Striatum
/ pathology
Cyclams
/ pharmacology
Disease Models, Animal
Disease Progression
Gene Expression Regulation
/ drug effects
Gene Ontology
Genetic Variation
Huntington Disease
/ genetics
Inflammation
/ pathology
Intercellular Signaling Peptides and Proteins
/ genetics
Longevity
/ genetics
Microglia
/ drug effects
Motor Activity
/ drug effects
Phosphoproteins
/ genetics
Proteasome Endopeptidase Complex
/ metabolism
Receptors, CXCR4
/ metabolism
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
18 07 2020
18 07 2020
Historique:
received:
07
04
2020
accepted:
03
07
2020
revised:
01
07
2020
entrez:
20
7
2020
pubmed:
20
7
2020
medline:
25
3
2021
Statut:
epublish
Résumé
The longevity-associated variant (LAV) of the bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4) has been found significantly enriched in long-living individuals. Neuroinflammation is a key player in Huntington's disease (HD), a neurodegenerative disorder caused by neural death due to expanded CAG repeats encoding a long polyglutamine tract in the huntingtin protein (Htt). Herein, we showed that striatal-derived cell lines with expanded Htt (STHdh Q
Identifiants
pubmed: 32683420
doi: 10.1038/s41419-020-02754-w
pii: 10.1038/s41419-020-02754-w
pmc: PMC7368858
doi:
Substances chimiques
Benzylamines
0
Bpifb4 protein, mouse
0
Cyclams
0
Intercellular Signaling Peptides and Proteins
0
Phosphoproteins
0
Receptors, CXCR4
0
Proteasome Endopeptidase Complex
EC 3.4.25.1
plerixafor
S915P5499N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
546Références
Reiner, A., Dragatsis, I. & Dietrich, P. Genetics and neuropathology of Huntington’s disease. Int. Rev. Neurobiol.98, 325–372 (2011).
pubmed: 21907094
pmcid: 4458347
doi: 10.1016/B978-0-12-381328-2.00014-6
Dayalu, P. & Albin, R. L. Huntington disease: pathogenesis and treatment. Neurol. Clin.33, 101–114 (2015).
pubmed: 25432725
doi: 10.1016/j.ncl.2014.09.003
pmcid: 25432725
Nance, M. A. Genetics of Huntington disease. Handb. Clin. Neurol.144, 3–14 (2017).
pubmed: 28947123
doi: 10.1016/B978-0-12-801893-4.00001-8
pmcid: 28947123
Vonsattel, J. P. Huntington disease models and human neuropathology: similarities and differences. Acta Neuropathol.115, 55–69 (2008).
pubmed: 17978822
doi: 10.1007/s00401-007-0306-6
pmcid: 17978822
Ross, C. A. & Tabrizi, S. J. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol.10, 83–98 (2011).
pubmed: 21163446
doi: 10.1016/S1474-4422(10)70245-3
pmcid: 21163446
Shannon, K. M. Huntington’s disease—clinical signs, symptoms, presyntomatic diagnosis, and diagnosis. Handb. Clin. Neurol.100, 3–13, https://doi.org/10.1016/b978-0-444-52014-2.00001-x (2011).
doi: 10.1016/b978-0-444-52014-2.00001-x
pubmed: 21496568
pmcid: 21496568
Garcia-Miralles, M. et al. Laquinimod treatment improves myelination deficits at the transcriptional and ultrastructural levels in the YAC128 mouse model of Huntington disease. Mol. Neurobiol.56, 4464–4478 (2019).
pubmed: 30334188
doi: 10.1007/s12035-018-1393-1
pmcid: 30334188
Carroll, J. Disappointing news from LEGATO-HD trial of laquinimod in Huntington’s disease. HDBuzz 1–4 (2018) https://en.hdbuzz.net/262.
Ransohoff, R. M. A polarizing question: do M1 and M2 microglia exist? Nat. Neurosci.19(8), 987–991 (2016).
pubmed: 27459405
doi: 10.1038/nn.4338
pmcid: 27459405
Nakagawa, Y. & Chiba, K. Diversity and plasticity of microglial cells in psychiatric and neurological disorders. Pharmacol. Ther.154, 21–35 (2015).
pubmed: 26129625
doi: 10.1016/j.pharmthera.2015.06.010
Liu, C. Y., Wang, X., Liu, C. & Zhang, H. L. Pharmacological targeting of microglial activation: new therapeutic approach. Front. Cell. Neurosci.13, 1–19 (2019).
Liu, G. et al. Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: Inhibition of inflammation by resolvin D1. Am. J. Neurodegener. Dis.1, 60–74 (2012).
pubmed: 22787561
pmcid: 3560453
Ferger, A. I. et al. Effects of mitochondrial dysfunction on the immunologicalproperties of microglia. Neuroinflammation7, 1–10 (2010).
doi: 10.1186/1742-2094-7-45
Palpagama, T. H., Waldvogel, H. J., Faull, R. L. M. & Kwakowsky, A. The Role of Microglia and Astrocytes in Huntington’s Disease. Front. Mol. Neurosci.12, 1–15 (2019).
doi: 10.3389/fnmol.2019.00258
Crotti, A. & Glass, C. K. The choreography of neuroinflammation in Huntington’s disease. Trends Immunol.36, 364–373 (2015).
pubmed: 26001312
pmcid: 4786070
doi: 10.1016/j.it.2015.04.007
Britto, C. J. & Cohn, L. Bactericidal/permeability-increasing protein fold-containing family member A1 in airway host protection and respiratory disease. Am. J. Respir. Cell Mol. Biol.52, 525–34 (2015).
pubmed: 25265466
pmcid: 4491141
doi: 10.1165/rcmb.2014-0297RT
Ciaglia, E. et al. Longevity-associated variant of BPIFB4 mitigates monocyte-mediated acquired immune response. J. Gerontol. A. Biol. Sci. Med. Sci.74(Supplement_1), S38–S44 (2019).
pubmed: 31074771
doi: 10.1093/gerona/glz036
Villa, F. et al. Serum BPIFB4 levels classify health status in long-living individuals. Immun. Ageing12, 1–7 (2015).
doi: 10.1186/s12979-015-0054-8
Ciaglia, E. et al. Circulating BPIFB4 levels associate with and influence the abundance of reparative monocytes and macrophages in Long Living Individuals. Front. Immunol.11, 1–8 (2020).
doi: 10.3389/fimmu.2020.01034
Villa, F. et al. Genetic analysis reveals a longevity-associated protein modulating endothelial function and angiogenesis. Circ. Res.117, 333–45 (2015).
pubmed: 26034043
pmcid: 5496930
doi: 10.1161/CIRCRESAHA.117.305875
Spinelli, C. C. et al. LAV-BPIFB4 isoform modulates eNOS signalling through Ca2+/PKC-alpha-dependent mechanism. Cardiovasc. Res.113, 5–804, https://doi.org/10.1093/cvr/cvx072 (2017).
doi: 10.1093/cvr/cvx072
Malavolta, M. et al. LAV-BPIFB4 associates with reduced frailty in humans and its transfer prevents frailty progression in old mice. Aging11, 6555–6568 (2019).
pubmed: 31461407
pmcid: 6738439
doi: 10.18632/aging.102209
Puca, A. A. et al. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. Eur. Heart J. 1–12 https://doi.org/10.1093/eurheartj/ehz459 (2019).
Ferrante, R. J. Mouse models of Huntington’s disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta1792, 506–520 (2009).
pubmed: 19362590
pmcid: 2693467
doi: 10.1016/j.bbadis.2009.04.001
Trettel, F. et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet.9, 2799–2809 (2000).
pubmed: 11092756
doi: 10.1093/hmg/9.19.2799
Konstantinova, I. M., Tsimokha, A. S. & Mittenberg, A. G. Role of proteasomes in cellular regulation. Int. Rev. Cell. Mol. Biol.267, 59–124 (2008).
pubmed: 18544497
doi: 10.1016/S1937-6448(08)00602-3
Chafekar, S. M. & Duennwald, M. L. Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS ONE7, e37929 (2012).
pubmed: 22649566
pmcid: 3359295
doi: 10.1371/journal.pone.0037929
Dang, Z et al. Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signalling pathway. Eur. J. Heart. Fail. (2020) https://doi.org/10.1002/ejhf.1840 .
Sánchez-Martín, L. et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood117, 88–97 (2011).
pubmed: 20930067
doi: 10.1182/blood-2009-12-258186
Terry, D. F., Sebastiani, P., Andersen, S. L. & Perls, T. T. Disentangling the roles of disability and morbidity in survival to exceptional old age. Arch. Intern. Med.168, 277–283 (2010).
doi: 10.1001/archinternmed.2007.75
Perls, T. T. et al. Life-long sustained mortality advantage of siblings of centenarians. Proc. Natl Acad. Sci. USA99, 8442–8447 (2002).
pubmed: 12060785
doi: 10.1073/pnas.122587599
pmcid: 12060785
Heyn, H. et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA109, 10522–10527(2012).
pubmed: 22689993
doi: 10.1073/pnas.1120658109
pmcid: 22689993
Hou, Y. et al. Ageing as a risk factor for neurodegenerative disease. Nat. Rev. Neurol.15, 565–581 (2019).
pubmed: 31501588
doi: 10.1038/s41582-019-0244-7
pmcid: 31501588
Ellrichmann, G., Reick, C., Saft, C. & Linker, R. The role of the immune system in Huntington’s disease. Clin. Dev. Immunol.2013, 541259 (2013).
pubmed: 23956761
pmcid: 3727178
doi: 10.1155/2013/541259
Simmons, D. A. et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia55, 1074–1084 (2007).
pubmed: 17551926
doi: 10.1002/glia.20526
pmcid: 17551926
Pavese, F. N. et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology66, 1638–1643 (2006).
pubmed: 16769933
doi: 10.1212/01.wnl.0000222734.56412.17
pmcid: 16769933
Tai, Y. F. et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain130, 1759–1766 (2007).
pubmed: 17400599
doi: 10.1093/brain/awm044
pmcid: 17400599
Politis, M. et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol. Dis.83, 115–121 (2015).
pubmed: 26297319
doi: 10.1016/j.nbd.2015.08.011
pmcid: 26297319
Yang, H. M., Yang, S., Huang, S. S., Tang, B. S. & Guo, J. F. Microglial activation in the pathogenesis of Huntington’s disease. Front. Aging Neurosci.9, 193 (2017).
pubmed: 28674491
pmcid: 5474461
doi: 10.3389/fnagi.2017.00193
Chang, K. H., Wu, Y. R., Chen, Y. C. & Chen, C. M. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav. Immun.44, 121–127 (2015).
pubmed: 25266150
doi: 10.1016/j.bbi.2014.09.011
pmcid: 25266150
Li, M. & Ransohoff, R. M. The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin. Cancer Biol.19, 111–115 (2009).
pubmed: 19038344
doi: 10.1016/j.semcancer.2008.11.001
pmcid: 19038344
Karin, N. The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J. Leukoc. Biol.88, 463–73 (2010).
pubmed: 20501749
doi: 10.1189/jlb.0909602
pmcid: 20501749
Wang, Q. et al. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer’s disease mouse model. Brain Res.12(1459), 15–26 (2012).
doi: 10.1016/j.brainres.2012.04.011
Carbajal, K. S., Schaumburg, C., Strieter, R., Kane, J. & Lane, T. E. Migration of engrafted neural stem cells is mediated by CXCL12 signaling through CXCR4 in a viral model of multiple sclerosis. Proc. Natl Acad. Sci. USA107, 11068–11073 (2010).
pubmed: 20534452
doi: 10.1073/pnas.1006375107
pmcid: 20534452
Chang, R., Liu, X., Li, S. & Li, X. J. Transgenic animal models for study of the pathogenesis of Huntington’s disease and therapy. Drug Des. Devel. Ther.9, 2179–2188 (2015).
pubmed: 25931812
pmcid: 4404937
Neueder, A. et al. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington’s disease patients. Sci. Rep.7, 1307 (2017).
pubmed: 28465506
pmcid: 5431000
doi: 10.1038/s41598-017-01510-z
Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell87, 493–506 (1996).
pubmed: 8898202
doi: 10.1016/S0092-8674(00)81369-0
pmcid: 8898202
Davies, S. W. & Scherzinger, E. Nuclear inclusions in Huntington’s disease. Trends Cell. Biol.7, 422 (1997).
pubmed: 17708997
doi: 10.1016/S0962-8924(97)88136-6
pmcid: 17708997
Carter, R. J. et al. Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J. Neurosci.19, 3248–3257 (1999).
pubmed: 10191337
pmcid: 6782264
doi: 10.1523/JNEUROSCI.19-08-03248.1999
Chalasani, S. H. et al. The chemokine stromal cell-derived factor-1 promotes the survival of embryonic retinal ganglion cells. J. Neurosci.23, 4601–4612 (2003).
pubmed: 12805300
pmcid: 6740796
doi: 10.1523/JNEUROSCI.23-11-04601.2003
Ciaglia, E. et al. N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice. Pharm. Res.89, 1–10 (2014).
doi: 10.1016/j.phrs.2014.07.003
Romero-Calvo, I. et al. Reversible Ponceau staining as a loading control alternative to actin in Western blots. Anal. Biochem.2, 318–320 (2010).
doi: 10.1016/j.ab.2010.02.036
Di Pardo, A. et al. Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington’s disease. Hum. Mol. Genet.14, 2490–2501 (2018).
doi: 10.1093/hmg/ddy153
Di Pardo, A. et al. Stimulation of sphingosine kinase 1 (SPHK1) is beneficial in a Huntington’s disease pre-clinical model. Front. Mol. Neurosci.12, 100 (2019).
pubmed: 31068790
pmcid: 6491579
doi: 10.3389/fnmol.2019.00100
Faul, F. et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods39, 175 91 (2007).
pubmed: 17695343
doi: 10.3758/BF03193146
Di Pardo, A. et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc. Natl Acad. Sci. USA109, 3528–3533 (2012).
pubmed: 22331905
doi: 10.1073/pnas.1114502109
Di Pardo, A. et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum. Mol. Genet.23, 2251–2265 (2014).
pubmed: 24301680
doi: 10.1093/hmg/ddt615
Martin, M. CUTADAPT removes adapter sequences from high-throughput sequencing reads. EMBnet J.17, 3 (2011).
doi: 10.14806/ej.17.1.200
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics29, 15–21 (2013).
pubmed: 23104886
pmcid: 23104886
doi: 10.1093/bioinformatics/bts635
Hubbard, T. et al. The Ensembl genome database project. Nucleic Acids Res.30, 38–41 (2002).
pubmed: 11752248
pmcid: 99161
doi: 10.1093/nar/30.1.38
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics30, 923–930 (2014).
pubmed: 24227677
pmcid: 24227677
doi: 10.1093/bioinformatics/btt656
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics26, 139–140 (2010).
pubmed: 19910308
pmcid: 19910308
doi: 10.1093/bioinformatics/btp616
Mi, H., Muruganujan, A. & Thomas, P. D. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res.41(Database issue), D377–D386 (2013).
pubmed: 23193289